Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers

Conclusion: EGFR gene amplification and mutations are rare in TNBC, the latter of no apparent clinical relevance. Surrogate markers of EGFR-related chromosomal aberrations and combined EGFR/p53 IHC phenotypes appear to be associated with favorable prognosis in patients with operable TNBC receiving conventional adjuvant chemotherapy.

Source: Cancer Genomics and Proteomics - April 26, 2017 Category: Cancer & Oncology Authors: LEVVA, S., KOTOULA, V., KOSTOPOULOS, I., MANOUSOU, K., PAPADIMITRIOU, C., PAPADOPOULOU, K., LAKIS, S., KOUKOULIAS, K., KARAVASILIS, V., PENTHEROUDAKIS, G., BALASSI, E., ZAGOURI, F., KAKLAMANOS, I. G., PECTASIDES, D., RAZIS, E., ARAVANTINOS, G., PAPAKOSTAS Tags: Article Source Type: research